The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma.
Michele Maio
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Jessica Cecile Hassel
Research Funding - Eisai
Michele Del Vecchio
No relevant relationships to disclose
Alessandro Testori
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline
Other Remuneration - Oucov
Paolo Antonio Ascierto
No relevant relationships to disclose
Ernie Marshall
No relevant relationships to disclose
Hiliary Glen
Research Funding - Eisai
Paul Lorigan
No relevant relationships to disclose
Elaine Meek
No relevant relationships to disclose
Song Liou
No relevant relationships to disclose
Jeff Paul Hodge
No relevant relationships to disclose
Fabrina Bologna
No relevant relationships to disclose
Harish P. Dave
No relevant relationships to disclose